Immune Globulin Thrombotic Class Labeling Precaution Requested By FDA
Executive Summary
Intravenous immune globulin manufacturers have until Jan. 14 to include a precaution in product labeling on thrombotic events, FDA says in a 1letter to manufacturers posted on the agency's website Dec. 15